Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1374846rdf:typepubmed:Citationlld:pubmed
pubmed-article:1374846lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:1374846lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:1374846lifeskim:mentionsumls-concept:C0012854lld:lifeskim
pubmed-article:1374846lifeskim:mentionsumls-concept:C0221198lld:lifeskim
pubmed-article:1374846lifeskim:mentionsumls-concept:C1511790lld:lifeskim
pubmed-article:1374846lifeskim:mentionsumls-concept:C0205214lld:lifeskim
pubmed-article:1374846lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:1374846pubmed:issue3lld:pubmed
pubmed-article:1374846pubmed:dateCreated1992-6-12lld:pubmed
pubmed-article:1374846pubmed:abstractTextThe abasic site is one of the most frequent changes occurring in DNA and has been shown to be lethal and mutagenic. An abasic site in DNA can be tagged by reaction with O-4-nitrobenzylhydroxylamine (NBHA), resulting in the formation of an oxime linkage between the abasic site and the NBHA moiety. In order to measure NBHA-tagged abasic sites, a monoclonal antibody was elicited against a 5'-phosphodeoxyribosyl O-4-nitrobenzyl hydroxylamine-BSA conjugate. The antibody was specific for the NBHA residue as demonstrated by hapten inhibition, with IC50 values for 5'-phosphodeoxyribosyl-NBHA, deoxyribosyl-NBHA, ribosyl-NBHA and NBHA of 0.3 microM, 5 microM, 5 microM and 7 microM, respectively. Other haptens examined, including benzylhydroxylamine, 5'-phosphodeoxyribosyl-, deoxyribosyl-, and ribosyl-benzylhydroxylamine, showed no inhibition even at 1 mM. The antibody showed high specificity for NBHA-modified AP sites in DNA and exhibited no cross reactivity with normal DNA bases, otherwise-modified DNA bases or unmodified AP sites. Using a direct ELISA assay, the antibody detected 1 AP site (after NBHA-modification) per 10,000 base-pairs or approximately 10 femtomoles of AP sites in DNA. DNA lesions were detectable in 60Co gamma-irradiated DNA at a dose as low as 10 rad (0.1 Gy) and the production of antibody detectable sites was proportional to the gamma-ray dose. Since NBHA reacts with lesions containing an aldehyde group, the simplicity and sensitivity of the antibody assay should provide a useful method for the quantitation of AP sites or other DNA lesions containing an aldehyde group.lld:pubmed
pubmed-article:1374846pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374846pubmed:languageenglld:pubmed
pubmed-article:1374846pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374846pubmed:citationSubsetIMlld:pubmed
pubmed-article:1374846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1374846pubmed:statusMEDLINElld:pubmed
pubmed-article:1374846pubmed:monthMaylld:pubmed
pubmed-article:1374846pubmed:issn0027-5107lld:pubmed
pubmed-article:1374846pubmed:authorpubmed-author:ErlangerB FBFlld:pubmed
pubmed-article:1374846pubmed:authorpubmed-author:KuboKKlld:pubmed
pubmed-article:1374846pubmed:authorpubmed-author:WallaceS SSSlld:pubmed
pubmed-article:1374846pubmed:authorpubmed-author:IdeHHlld:pubmed
pubmed-article:1374846pubmed:authorpubmed-author:KowY WYWlld:pubmed
pubmed-article:1374846pubmed:authorpubmed-author:ChenB XBXlld:pubmed
pubmed-article:1374846pubmed:issnTypePrintlld:pubmed
pubmed-article:1374846pubmed:volume273lld:pubmed
pubmed-article:1374846pubmed:ownerNLMlld:pubmed
pubmed-article:1374846pubmed:authorsCompleteYlld:pubmed
pubmed-article:1374846pubmed:pagination253-61lld:pubmed
pubmed-article:1374846pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:meshHeadingpubmed-meshheading:1374846-...lld:pubmed
pubmed-article:1374846pubmed:year1992lld:pubmed
pubmed-article:1374846pubmed:articleTitleProperties of a monoclonal antibody for the detection of abasic sites, a common DNA lesion.lld:pubmed
pubmed-article:1374846pubmed:affiliationDepartment of Microbiology, Columbia University, College of Physicians and Surgeons, New York, NY 10032.lld:pubmed
pubmed-article:1374846pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1374846pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:1374846pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed